Aruvant Sciences

sickle cell injection
Dick Whipple / AP

Cincinnati Children's is partnering with the Swiss company Roivant on a new venture called Aruvant Sciences, a biopharmaceutical company focusing on innovative gene therapies for hematological conditions such as sickle cell disease. Terms of the deal aren't disclosed in the news release, however, the Cincinnati Business Courier reports it's the hospital's biggest commercialization deal ever.